The Antioxidant Protein Peroxiredoxin 4 Is Epigenetically Down Regulated in Acute Promyelocytic Leukemia
2011

The Role of Peroxiredoxin 4 in Acute Promyelocytic Leukemia

Sample size: 461 publication Evidence: high

Author Information

Author(s): Palande Karishma K., Beekman Renee, van der Meeren Lotte E., Beverloo H. Berna, Valk Peter J. M., Touw Ivo P.

Primary Institution: Erasmus University Medical Center

Hypothesis

Is PRDX4 expression affected in acute promyelocytic leukemia (APL)?

Conclusion

PRDX4 expression is significantly reduced in APL compared to other types of acute myeloid leukemia.

Supporting Evidence

  • PRDX4 expression levels were found to be 4 to 5 times lower in APL compared to other AML samples.
  • Genomic abnormalities involving PRDX4 are rare in AML.
  • Reduced PRDX4 expression in APL is associated with increased trimethylation of histone marks at the transcriptional start site.

Takeaway

This study found that a protein called PRDX4, which helps protect cells from damage, is much lower in a type of leukemia called APL, which might make the disease worse.

Methodology

The study analyzed PRDX4 expression levels in myeloid leukemia patients using gene expression arrays and Western blot analysis.

Limitations

The study focused only on APL and did not explore other potential factors affecting PRDX4 expression.

Participant Demographics

The study included 461 myeloid leukemia patients, with specific focus on APL patients.

Statistical Information

P-Value

<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1371/journal.pone.0016340

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication